Investors - Poised for sustainable success

Current outlook

Outlook 2017/18 as of May 16, 2017

We expect to achieve continued solid growth in sales and profitability in both the hearing instruments and cochlear implants segments during 2017/18.

The development will be supported by our attractive product and solutions portfolio as well as our continued commitment to innovation. Coupled with the annualization of prior year acquisitions, in particular AudioNova, we expect overall sales to grow in the range of 10% – 12% in local currencies.

Sales*

in percentage

Guidance
FY 2017/18

Sales growth in local currencies +10%-12%
thereof M&A ca. + 6%

EBITA*

in percentage Guidance
FY 2017/18
EBITA growth in local currencies +10%-14%

* EBITA FY 2016/17 and FY 2017/18 excluding one-time transaction and integration costs related to AudioNova acquisition

 

While actual reported results may vary based on currency fluctuations, Sonova continues to mitigate the impact of the strong Swiss franc on earnings growth through its long-term global resource allocation strategy. 

Sensitivities*: A strengthening of the USD by 5% would affect sales in the financial year by approximately CHF +43 Mio. and EBITA by approximately CHF +10 Mio. The corresponding effect of a 5% stronger EUR would be CHF +45 Mio. on sales and CHF +18 Mio. on EBITA.